Stocks Health care ALDX
NASDAQ · Health careAldeyra Therapeutics, Inc. (ALDX)
It posted a net loss of $23.1M. At June 30, 2026 it held $45.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
Key facts about Aldeyra Therapeutics, Inc.
- Net worth
- Aldeyra Therapeutics, Inc. has a market value (market cap) of $38.4M at the latest share price, and shareholders' equity of $37.9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $33.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 6, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Aldeyra Therapeutics, Inc.'s next report was expected around November 4, 2026 and is not on file with the SEC yet.
What Aldeyra Therapeutics, Inc. does
Aldeyra Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ALDX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$33.8M | -$0.56 | n/a |
| 2024 | n/a | -$55.9M | -$0.94 | n/a |
| 2023 | n/a | -$37.5M | -$0.64 | -$30.3M |
| 2022 | n/a | -$62M | -$1.06 | -$56.7M |
| 2021 | n/a | -$57.8M | -$1.07 | -$42.6M |
| 2020 | n/a | -$37.6M | -$1.11 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Aldeyra Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 29, 2026
- August 12, 2026Passive stake (5% or more) SCHEDULE 13G
- August 6, 2026
- July 30, 2026
- July 27, 2026Passive stake changed SCHEDULE 13G/A
- July 15, 2026Other event 8-K
- June 10, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 7, 2026
- May 1, 2026
Insider trades
What the people running Aldeyra Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 3, 2026 | Brady Todd CPresident and CEO, Director | Bought | 250,000 | $418.5K |
| March 19, 2026 | Douglas RichardDirector | Bought | 70,000 | $98K |
| March 18, 2026 | Alfieri MichaelPrincipal Financial Officer | Bought | 5,000 | $7.1K |
Who owns ALDX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| AQR Capital Management, LLC13G, passive with 1 related filers | 6.22% | August 12, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 108 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Knoll Capital Management, LLC | 5,475,516 | 0 |
| Aqr Capital Management LLC | 3,751,558 | +921,683 |
| Kingdon Capital Management, L.L.C. | 2,652,315 | +500,000 |
| Vanguard Capital Management LLC | 2,361,796 | -1,946 |
| D. E. Shaw & Co., Inc. | 1,940,338 | +536,348 |
| Marshall Wace, Llp | 1,506,974 | +1,377,281 |
| 683 Capital Management, LLC | 1,450,000 | -50,000 |
| Jane Street Group, LLC | 1,375,115 | +406,224 |
| BlackRock, Inc. | 1,257,243 | -2,506,644 |
| Qube Research & Technologies Ltd | 1,128,803 | +1,041,725 |
| Ardsley Advisory Partners LP | 975,000 | +25,000 |
| Renaissance Technologies LLC | 882,000 | +18,813 |
| Vanguard Portfolio Management LLC | 794,863 | -12,915 |
| Goldman Sachs Group Inc | 725,444 | +182,298 |
| Jacobs Levy Equity Management, Inc | 646,840 | -149,976 |
| Morgan Stanley | 608,321 | +89,679 |
| Geode Capital Management, LLC | 596,029 | -655,623 |
| Dimensional Fund Advisors LP | 529,083 | -95,087 |
| Arrowstreet Capital, Limited Partnership | 421,178 | new |
| Cantor Fitzgerald, L. P. | 400,000 | new |
Insiders
3 insiders reported holding 1,923,798 shares in total, about $1.2M at the last price.
| Holder | Shares |
|---|---|
| Brady Todd CPresident and CEO, Director | 1,721,298 |
| Douglas RichardDirector | 195,000 |
| Alfieri MichaelPrincipal Financial Officer | 7,500 |
Questions about ALDX
What does Aldeyra Therapeutics, Inc. do?
Aldeyra Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as ALDX. Its shares trade on NASDAQ under the ticker ALDX.
What is Aldeyra Therapeutics, Inc.'s net worth?
Aldeyra Therapeutics, Inc. has a market value (market cap) of $38.4M at the latest share price, and shareholders' equity of $37.9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Aldeyra Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $23.1M.
When did Aldeyra Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from September 29, 2026.
When is Aldeyra Therapeutics, Inc.'s next earnings report?
Aldeyra Therapeutics, Inc.'s next report was expected around November 4, 2026 and is not on file with the SEC yet.
Similar companies
Compare ALDX with
Follow ALDX
Get an email when Aldeyra Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Aldeyra Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.